About MUSCUMET LLC
MuscuMet is a pre-clinical stage biotechnology company developing TMet1, a topical treatment for tendon injuries, with research supported by the Department of Defense. The company focuses on regenerative pharmacology to address tendinopathy and accelerate healing without fibrotic scarring.
Development of topical and injectable treatments for tendon injuriesPre-clinical drug development with extensive animal testingResearch on regenerative pharmacology and mechanobiology
Is this your company?
Claim MUSCUMET LLC to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim MUSCUMET LLC & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.